• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Authors » Steve Balt, MD
Steve Balt, MD

Steve Balt, MD

Research fellow, Addiction Pharmacology Research Laboratory, California Pacific Medical Center
Articles

ARTICLES

Four Newer Antidepressants: Should You Use Them?

April 1, 2016
Steve Balt, MD and Talia Puzantian, PharmD, BCPP
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
BaltSteve Balt, MD Research fellow, Addiction Pharmacology Research Laboratory, California Pacific Medical Center Dr. Balt discloses that his spouse is employed as a sales representative for Bristol Myers Squibb.       Talia PuzantianTalia Puzantian, PharmD, BCPP Clinical psychopharmacology consultant in private practice, Los Angeles, CA. Dr. Puzantian has disclosed that she has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
Since 2011, 3 new antidepressants have been approved by the FDA, and another (ketamine) has been generating buzz as a potential off-label medication for depression. In this article, we’ll take a step back and review the data on vilazodone (Viibryd), levomilnacipran (Fetzima), vortioxetine (Brintellix), and ketamine.
Read More

Does Brintellix Bring Anything New?

November 1, 2013
Steve Balt, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Steve Balt, MD Research fellow, Addiction Pharmacology Research Laboratory, California Pacific Medical Center Dr. Balt discloses that his spouse is employed as a sales representative for Bristol Myers Squibb.
After a dry spell of new antidepressants—the last one to be approved was levomilnacipran (Fetzima), the active enantiomer of milnacipran (Savella) in July 2013—the FDA approved vortioxetine (Brintellix) in September. Vortioxetine is another serotonergic antidepressant. How exactly does it work, and what are its advantages over existing drugs?
Read More

Future Developments in Antidepressant Therapy

May 1, 2012
Kelly Gable, PharmD, BCPP and Steve Balt, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Kelly Gable, PharmD, BCPP Assistant professor of pharmacy practice, Southern Illinois University, Edwardsville, School of Pharmacy Dr. Gable has disclosed that she has no relevant relationships or financial interests in any commercial companies pertaining to this educational activity. Steve Balt, MD Research fellow, Addiction Pharmacology Research Laboratory, California Pacific Medical Center Dr. Balt discloses that his spouse is employed as a sales representative for Bristol Myers Squibb.
In 2011 in the pages of TCPR, we asked, “What’s new in antidepressant treatment?” The answer was “not much” (TCPR, April 2011). In 2012, unfortunately, the answer isn’t very different.
Read More

Deplin: Is it Just Folate by Another Name?

January 1, 2012
Steve Balt, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Steve Balt, MD Research fellow, Addiction Pharmacology Research Laboratory, California Pacific Medical Center Dr. Balt discloses that his spouse is employed as a sales representative for Bristol Myers Squibb.
Patients are probably asking you about Deplin, or L-methylfolate, a version of folic acid that is being marketed by Pamlab as an adjunctive treatment for depression.
Read More

Nuedexta for Pseudobulbar Affect

January 1, 2012
Steve Balt, MD and Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Steve Balt, MD Research fellow, Addiction Pharmacology Research Laboratory, California Pacific Medical Center Dr. Balt discloses that his spouse is employed as a sales representative for Bristol Myers Squibb. Daniel Carlat, MD
Editor-in-Chief, Publisher, The Carlat Report.
Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
Nuedexta is a combination of dextromethorphan (DM) and quinidine sulfate. You might reasonably ask why these two agents would have ever been considered as a treatment for PBA.
Read More
Share Your Clinical Interests

Completing this brief survey will help us send you materials relevant to your practice.

Take The Survey
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • CMFB2e_Cover.png

    (PRE-ORDER) Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto84222831.jpg
    General Psychiatry

    The Adderall Shortage

    Adderall is in short supply, and the backlog is having a domino effect on other stimulants. Find out why, and how long it will last.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.